Results 11 to 20 of about 387,985 (305)
Современная ревматология, 2021 Objective: to assess the frequency of prescription, efficacy and tolerability of biological disease-modifying antirheumatic drugs (bDMARDs) therapy in patients with major monogenic autoinflammatory diseases (mAID) according to the Federal Rheumatology ...
S. O. Salugina +2 more
doaj +1 more source
Frontiers in Oncology, 2022 The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera +1 more
doaj +1 more source
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]
, 2020 Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra +3 more
core +1 more source
Journal of Orthopaedic Surgery and Research, 2023 Objective We aimed to evaluate the efficacy and safety of anti-interleukin-1 therapeutics, including IL-1 antibodies, interleukin-1 receptor antagonists (IL-1 Ras) and IL-1 inhibitors, for knee osteoarthritis (KOA) treatment.
Lizhi Yu +4 more
doaj +1 more source
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis
Frontiers in Medicine, 2020 Sarcoidosis is a multisystem granulomatous disease of unknown origin that has variable clinical course and can affect nearly any organ. It has a chronic course in about 25% of patients.
Gonçalo Boleto +18 more
doaj +1 more source
Frontiers in Immunology, 2020 In December 2019, following a cluster of pneumonia cases in China caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection disseminated worldwide and, on March 11th, 2020, the World Health ...
Serena Colafrancesco +4 more
doaj +1 more source
ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES
Научно-практическая ревматология, 2016 According to the predominant mechanisms of immunity activation, human inflammatory diseases are divided into two main categories: autoimmune and autoinflammatory ones.
E. L. Nasonov, M. S. Eliseev
doaj +1 more source
Disruption of Interleukin-1β Autocrine Signaling Rescues Complex I Activity and Improves ROS Levels in Immortalized Epithelial Cells with Impaired Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function [PDF]
, 2014 Patients with cystic fibrosis (CF) have elevated concentration of cytokines in sputum and a general inflammatory condition. In addition, CF cells in culture produce diverse cytokines in excess, including IL-1B. We have previously shown that IL-1B, at low
Clauzure, Mariangeles +5 more
core +1 more source
Monogenic auto-inflammatory diseases in children and adults: what a rheumatologist should know
Научно-практическая ревматология, 2019 The article presents information on the current state of the problem of autoinflammatory diseases (AID) in rheumatology, reflects the clinical and demographic, laboratory and molecular genetic characteristics of the main monogenic AID (mAID), the most ...
S. O. Salugina +2 more
doaj +1 more source